TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Aim to Reduce Movements in Tardive Dyskinesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of using a dopamine receptor antagonist for at least 3 months~* Clinical diagnosis of tardive dyskinesia and has had symptoms for at least 3 months prior to screening~* Subjects with underlying psychiatric diagnosis are stable and have no change in psychoactive medications~* Have a mental health provider and does not anticipate any changes to treatment regimen in the next 3 months~* History of being compliant with prescribed medications~* Able to swallow study drug whole~* Be in good general health and is expected to attend all study visits and complete study assessments~* Female subjects must not be pregnant and agree to an acceptable method of contraception~Exclusion Criteria:~* Currently receiving medication for the treatment of tardive dyskinesia~* Have a neurological condition other than tardive dyskinesia that may interfere with assessing the severity of dyskinesias~* Have a serious untreated or undertreated psychiatric illness~* Have recent history or presence of violent behavior~* Have unstable or serious medical illness~* Have evidence of hepatic impairment~* Have evidence of renal impairment~* Have known allergy to any component of SD-809 or tetrabenazine~* Has participated in an investigational drug or device trial and received study drug within 30 days~* Have acknowledged use of illicit drugs~* Have a history of alcohol or substance abuse in the previous 12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- SD-809 (Type: EXPERIMENTAL): SD-809 tablets taken twice daily for 12 weeks.
- Sugar Pill (Type: PLACEBO_COMPARATOR): Placebo tablets taken twice daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Inadequate glycemic control on diet/exercise therapy and sitagliptin monotherapy~* HbA1c ≥7.0% and ≤10.0% before study start~Exclusion Criteria:~* History of Type 1 diabetes mellitus or a history of ketoacidosis~* History of any of the following medications: thiazolidinediones (TZD) and/or insulin within 12 weeks prior to study participation and sodium glucose cotransporter 2 (SGLT2) inhibitors anytime~* Currently has a urinary tract infection or genital infection with subjective symptom

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ipragliflozin + Sitagliptin (Type: EXPERIMENTAL): Ipragliflozin once daily for 24 weeks in addition to sitagliptin, diet, and exercise.
- Placebo + Sitagliptin (Type: ACTIVE_COMPARATOR): Placebo to ipragliflozin once daily for 24 weeks in addition to sitagliptin, diet, and exercise.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females aged 6 years or older.~* A confirmed diagnosis of HAE type I or II.~* HAE attacks over a consecutive 2-month period that required acute treatment, medical attention, or caused significant functional impairment.~* For subjects who have used oral therapy for prophylaxis against HAE attacks within 3 months of first study visit: use of a stable regimen within 3 months of the first study visit.~Exclusion Criteria:~* Incurable malignancies.~* Any clinical condition that will interfere with the evaluation of C1-INH therapy.~* Clinically significant history of poor response to C1-esterase therapy for the management of HAE.~* Suspected or confirmed diagnosis of acquired HAE or HAE with normal C1-INH.~* Inability to have HAE managed pharmacologically with on-demand treatment.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- C1-INH - low-volume dose (Type: EXPERIMENTAL): A low-volume dose of C1-INH will be administered subcutaneously twice a week for up to 52 weeks (up to 146 weeks extension period).
- C1-INH - medium-volume dose (Type: EXPERIMENTAL): A medium-volume dose of C1-INH will be administered subcutaneously twice a week for up to 52 weeks (up to 146 weeks extension period).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have been diagnosed with type 2 diabetes.~* Have suboptimal glycemic control as evidenced by an HbA1c between 7.1% and 11.0% inclusive.~* Have a body mass index (BMI) of \>21 kg/m2 and \<35 kg/m2, inclusive.~* Have a history of stable body weight (not varying by \>5% for at least 90 days prior to study start).~* Have been treated with a stable dose regimen of Met, SU, TZD, Met plus SU, Met plus TZD, or SU plus TZD for at least 90 days prior to study start.~Exclusion Criteria:~* Have any contraindication for the OAD(s) that they use.~* Have a known allergy or hypersensitivity to exenatide BID, exenatide QW, or excipients contained in these agents.~* Have received chronic \>14 consecutive days) systemic glucocorticoid therapy by oral, intravenous (IV), or intramuscular (IM) route or intra-articular steroid injection within 4 weeks prior to study start or are regularly treated with potent, inhaled steroids that are known to have a high rate of systemic absorption.~* Have been treated with drugs that promote weight loss (for example, GLP-1 analogue, orlistat, sibutramine, phenylpropanolamine, or similar over-the-counter medications) within 90 days of study start.~* Have been treated for \>2 weeks with any of the following excluded medications within 90 days prior to study start:~  * Insulin~ * Dipeptidyl peptidase (DPP)-4 inhibitors (for example, sitagliptin or vildagliptin)~ * Pramlintide acetate~ * Drugs that directly affect gastrointestinal motility, including, but not limited to: Reglan® (metoclopramide), Propulsid® (cisapride), and chronic macrolide antibiotics.~* Have had prior exposure to exenatide~* Have previously completed or withdrawn from this study or any other study investigating exenatide BID or QW.~* Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.~* Are currently enrolled in any other clinical study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer~* No prior chemotherapy~* Age: 20 and more~* Performance status: ECOG 0-3~* 1) Absolute neutrophil count at least 1,500/mm3 2) Platelet count at least 100,000/mm3 3) Bilirubin less than 1.5mg/dL 4) SGOT less than 100 IU/l 5) Serum creatinine less than 1.5mg/dL~* Written informed consent~Exclusion Criteria:~* Patients with ovarian borderline tumor~* Patients who have any evidence of the other cancer present within the last 5 years with the exception of carcinoma in situ or intramucosal cancer that is curable with local therapy~* Patients with active infection or uncontrolled diabetes~* Patients with unstable angina, or those who have had a myocardial infarction within the past 6 months, or patients with serious arrythmia that requires medication~* Patients who have a history of hypersensitivity to polyoxyethylated castor oil (Cremophor EL)

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Drug: Paclitaxel 180mg/m2＋CBDCA AUC6 q21 days x 6-9cycles
- 2 (Type: EXPERIMENTAL): Drug: Paclitaxel 80mg/m2 weekly ＋CBDCA AUC6 q21 days x 6-9cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of wAMD.~* Patients for whom the decision to initiate treatment with IVT aflibercept in a proactive regimen was made as routine clinical practice.~* Treatment-naïve in the study eye (no prior therapy for wAMD).~* Patient age ≥50 years of age.~* Written informed patient consent before the start of data collection (according to the requirements of the local authorities and laws).~Exclusion Criteria:~* Participation in an investigational program with interventions outside of routine clinical practice.~* Patients with contraindications to IVT aflibercept listed in the local marketing authorization.~* Planned treatment regimen outside of the local marketing authorization.~* Patients with eye diseases, e.g. advanced glaucoma or visually significant cataracts, likely to require surgery during the observation period in the study eye.~* Concomitant ocular or systemic administration of drugs up to 3 months before IVT aflibercept treatment that could interfere with or potentiate the mechanism of action of IVT aflibercept, including other anti-VEGF agents in the fellow eye.~* Any other retinal disease which may interfere with the treatment of wAMD.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- wAMD patients (Type: None): Patients with a diagnosis of wAMD and naïve to any treatment in the study eye will be enrolled after the decision by treating physician for IVT aflibercept therapy according to the local label.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* adult~* rheumatoid arthritis~* group 1: initiating etanercept as first biologic therapy~* group 2: DAS28\<4.2, biologic naive and treated with non-biologic DMARDs~Exclusion Criteria:~* diagnosis of other inflammatory arthritis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- etanercept (Type: None): adult rheumatoid arthritis patients initiating therapy with etanercept as their first biologic therapy
- nbDMARD (Type: None): biologic-naive adult rheumatoid arthritis patients with DAS28 \>4.2 treated with non-biologic anti-rheumatic drugs(s).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antibiotics in Free Flaps Reconstructions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any patient who required reconstructive surgery for oncological reasons within the oral cavity with microvascular free flaps.~Exclusion Criteria:~* Healthy humans.~* Patients receiving preoperative neoadjuvant or previous adjuvant radiation therapy in their medical history.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- control (Type: NO_INTERVENTION): no antibiotics
- experimental group (Type: ACTIVE_COMPARATOR): drug administration (antibiotic)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Aripiprazole (Abilify) in Children With Symptoms of Mania

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients ages 4-9 years (inclusive)~* Patients who are anticipated to have a Young Mania Rating Scale (Young et al. 1978) of 15 or higher at baseline~* Meet DSM-IV criteria for bipolar disorder type 1 or 2, cyclothymia, or bipolar disorder not otherwise specified (BP NOS) based on the results of both a semi-structured diagnostic research assessment (K-SADS-PL supplemented with mood disorder sections from the WASH-U K-SADS) (Geller et al., 2001; Kaufman et al., 1997) and a clinical interview with a child and adolescent psychiatrist.~Exclusion Criteria:~* Patients who have a history of intolerance to APZ at doses of 0.1mg/kg/day~* Patients who have experienced a manic episode with a documented APZ dose as monotherapy treatment of 0.2 mg/kg/day~* Patients with an active neurological/medical disorder for which treatment with APZ would be contraindicated~* Patients with clinical evidence of autistic disorder, Asperger's disorder, Rett's syndrome or other pervasive developmental disorders~* Patients with clinical evidence of mental retardation~* Patients who are known to be allergic or hypersensitive to aripiprazole~* Patients who are unable to swallow pills/capsules~* Patients for whom the need for hospitalization during the course of the study appears likely~* Patients who have a general medical or neurological condition (including clinically significant abnormalities on screening laboratories) that may be considered to be the etiology of the patient's mood disorder~* Patients who have a general medical or neurological condition for which treatment with an atypical antipsychotic would be contraindicated (e.g. tardive dyskinesia)~* Patients who have a general medical or neurological condition that could interfere with the interpretation of clinical response to APZ treatment~* Patients taking psychotropic agents (other than psychostimulants) within one week of baseline (2 weeks for fluoxetine; 3 days for psychostimulants)

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 9 Years
- Healthy Volunteers: t

Study Arms:
- Aripiprazole (Type: ACTIVE_COMPARATOR): Phase I and Phase III are open label Abilify phases where all subjects receive active Abilify
- Placebo (Type: PLACEBO_COMPARATOR): in Phase 2 subjects are randomized to either placebo or abilify for up to 72 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety Study of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Had completed the phase 2 dose-ranging study (i.e., the subject had completed the study visit at Week 12).~Exclusion Criteria:~* Had clinical manifestations of hepatic impairment (e.g., an aspartate aminotransferase or alanine aminotransferase value 2.5 times or more of the upper reference limit at Week 8 of treatment in the phase 2 dose-ranging study).~* Had clinical manifestations of renal impairment (e.g., a creatinine value of 2 mg/dL or more at Week 8 of treatment in the phase 2 dose-ranging study).

- Gender: ALL
- Minimum Age: 33 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID (Type: EXPERIMENTAL): None
- Alogliptin 25 mg QD and Voglibose 0.2 mg TID (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years of age~* high risk uterine LMS, FIGO stage I or II~* pathology review of LMS high grade and /or mitotic rate greater than or equal to 5 mitoses/10 hpf~* no longer than 12 weeks from surgical resection of cancer~* no evidence of residual disease~* ECOG 0 or 1~* ANC ≥ 1,500, hemoglobin ≥ 8.0, platelets ≥100,000~* creatinine ≤ 1.5 x institutional upper limits of normal~* adequate liver function~* neuropathy (sensory and motor) ≤ CTC grade 1~* negative pregnancy test~* signed consent~Exclusion Criteria:~* patients with other invasive malignancies~* prior therapy with gemcitabine or docetaxel or doxorubicin~* hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80~* women who are breast feeding~* cardiac ejection fraction \<50%~* prior pelvic irradiation~* treatment with hormone replacement or anti-hormonal agents or other cytotoxic agents

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- gemcitabine/docetaxel then doxorubicin (Type: OTHER): Gemcitabine 900 mg/m2 IV over 90 minutes days 1 and 8 Docetaxel 75 mg/m2 IV day 8 (pre-medication dexamethasone 4-8 mg p.o. bid for 3 days, starting 12-24 hours prior to docetaxel). Doxorubicin 60 mg/m2 IVP every 21 days for 4 cycles (recommend use of central venous catheter access).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Positive Pressure at Induction of Anesthesia in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pre-school children, ASA physical status I or II, Children undergoing general anesthesia for elective surgery~Exclusion Criteria:~* Pre-existing parenchymal lung disease, Children cyanotic or with oxyhemoglobin saturation less than 95% before anesthetic induction, Recent history (\<4 weeks) or current upper respiratory tract infection

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 6 Years
- Healthy Volunteers: t

Study Arms:
- CPAP (Type: EXPERIMENTAL): None
- Control (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Men and women 18 years of age or older who have been taking glucocorticoid treatment. Men and women who are less than 50 years of age must have had a fracture as an adult to be eligible. Men and women who are 50 years of age or older who have been taking glucocorticoids must meet protocol-specific BMD criteria.~Exclusion Criteria:~Use of agents affecting bone metabolism, use of more than one biologic agent for inflammatory disease, history of bone disease (except osteoporosis), low vitamin D level (one can enter the trial after vitamin D levels are corrected), abnormalities of blood calcium, an underactive or overactive thyroid condition that is not treated and stable, Addison's disease, any abnormality of the parathyroid glands (the glands that control blood calcium), currently pregnant or planning a pregnancy, currently breast feeding, and other criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Denosumab (Type: EXPERIMENTAL): Participants received 60 mg denosumab by subcutaneous injection on day 1 and at months 6, 12, and 18. Participants also received placebo to risedronate orally once a day for 24 months.
- Risendronate (Type: EXPERIMENTAL): Participants received 5 mg risedronate orally once a day for 24 months and placebo to densumab by subcutaneous injection on day 1 and at months 6, 12, and 18.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete